Novartis AG
NVS112.030USD
+0.150+0.13%
Horário de mercado 03/06, 10:39（ET）Cotações atrasadas em 15 min
221.26BValor de mercado
18.53P/L TTM
Informações de Novartis AG Empresa
Informações da empresa
Código da empresaNVS
Nome da EmpresaNovartis AG
Data de listagemMay 07, 2001
Fundado em1996
CEODr. Vasant (Vas) Narasimhan, M.D.
Funcionários75883
Tipo de TítulosOrdinary Share
Fim do ano fiscalMay 07
EndereçoLichtstrasse 35
CidadeBASEL
Bolsa de ValoresJohannesburg Stock Exchange
PaísSwitzerland
Código postal4056
Telefone41613241111
Sitehttps://www.novartis.com/
Código da empresaNVS
Data de listagemMay 07, 2001
Fundado em1996
Executivos da Empresa
Nome
Nome/Posição
Posição
Ações Detidas
Variação
Mr. Patrick Horber, M.D.
Mr. Patrick Horber, M.D.
President - International, Member of the Executive Committee
President - International, Member of the Executive Committee
--
--
Ms. Ana de Pro Gonzalo
Ms. Ana de Pro Gonzalo
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Charles L. Sawyers, M.D.
Dr. Charles L. Sawyers, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John D. Young
Mr. John D. Young
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert (Rob) Kowalski
Dr. Robert (Rob) Kowalski
Chief People and Organization Officer, Member of the Executive Committee
Chief People and Organization Officer, Member of the Executive Committee
--
--
Dr. Fiona H. Marshall, Ph.D.
Dr. Fiona H. Marshall, Ph.D.
President - Biomedical Research, Member of the Executive Committee
President - Biomedical Research, Member of the Executive Committee
--
--
Dr. Shreeram Aradhye, M.D.
Dr. Shreeram Aradhye, M.D.
President - Global Drug Development and Chief Medical Officer, Member of the Executive Committee
President - Global Drug Development and Chief Medical Officer, Member of the Executive Committee
--
--
Dr. Simon E. Moroney
Dr. Simon E. Moroney
Independent Non-Executive Vice Chairman of the Board
Independent Non-Executive Vice Chairman of the Board
--
--
Ms. Karen L. Hale
Ms. Karen L. Hale
Chief Legal Officer, Member of the Executive Committee
Chief Legal Officer, Member of the Executive Committee
--
--
Dr. Steffen Lang, Ph.D.
Dr. Steffen Lang, Ph.D.
President - Operations, Member of the Executive Committee
President - Operations, Member of the Executive Committee
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações Detidas
Variação
Mr. Patrick Horber, M.D.
Mr. Patrick Horber, M.D.
President - International, Member of the Executive Committee
President - International, Member of the Executive Committee
--
--
Ms. Ana de Pro Gonzalo
Ms. Ana de Pro Gonzalo
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Charles L. Sawyers, M.D.
Dr. Charles L. Sawyers, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John D. Young
Mr. John D. Young
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert (Rob) Kowalski
Dr. Robert (Rob) Kowalski
Chief People and Organization Officer, Member of the Executive Committee
Chief People and Organization Officer, Member of the Executive Committee
--
--
Dr. Fiona H. Marshall, Ph.D.
Dr. Fiona H. Marshall, Ph.D.
President - Biomedical Research, Member of the Executive Committee
President - Biomedical Research, Member of the Executive Committee
--
--
Detalhamento da Receita
Moeda: USDTempo de atualização: qua, 5 de mar
Moeda: USDTempo de atualização: qua, 5 de mar
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Rest of portfolio
10.07B
20.01%
Cardiovascular, Renal and Metabolism - Entresto
7.82B
15.54%
Immunology - Cosentyx
6.14B
12.20%
Neuroscience - Kesimpta
3.22B
6.40%
Oncology -Kisqali
3.03B
6.02%
Other
20.02B
39.79%
Por RegiãoUSD
Nome
Receita
Proporção
United States
21.14B
42.02%
Other Foreign-
18.51B
36.79%
China
3.89B
7.73%
Germany
3.66B
7.27%
France
1.79B
3.56%
Switzerland
1.31B
2.61%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Rest of portfolio
10.07B
20.01%
Cardiovascular, Renal and Metabolism - Entresto
7.82B
15.54%
Immunology - Cosentyx
6.14B
12.20%
Neuroscience - Kesimpta
3.22B
6.40%
Oncology -Kisqali
3.03B
6.02%
Other
20.02B
39.79%
Acionista
Tempo de atualização: sex, 21 de fev
Tempo de atualização: sex, 21 de fev
Estatísticas do Acionista
Tipo
Estatísticas do Acionista
Acionista
Proporção
Dodge & Cox
0.61%
PRIMECAP Management Company
0.55%
Dimensional Fund Advisors, L.P.
0.41%
Loomis, Sayles & Company, L.P.
0.28%
Franklin Mutual Advisers, LLC
0.21%
Other
97.91%
Estatísticas do Acionista
Acionista
Proporção
Dodge & Cox
0.61%
PRIMECAP Management Company
0.55%
Dimensional Fund Advisors, L.P.
0.41%
Loomis, Sayles & Company, L.P.
0.28%
Franklin Mutual Advisers, LLC
0.21%
Other
97.91%
Tipo
Acionista
Proporção
Investment Advisor
3.30%
Investment Advisor/Hedge Fund
2.63%
Research Firm
0.34%
Hedge Fund
0.28%
Bank and Trust
0.12%
Holding Company
0.04%
Pension Fund
0.02%
Other
93.22%
Instituição Participações
Tempo de atualização: qui, 20 de fev
Tempo de atualização: qui, 20 de fev
Período do Relatório
Nº de instituições
Ações detidas
Proporção
Variação
2025Q1
1868
133.88M
6.78%
-8.72M
2024Q4
1926
133.99M
6.78%
-9.23M
2024Q3
1858
134.89M
6.74%
-11.71M
2024Q2
1840
139.20M
6.87%
-9.16M
2024Q1
1808
141.29M
6.92%
-7.92M
2023Q4
1811
141.98M
6.94%
-15.97M
2023Q3
1775
150.91M
7.33%
-7.18M
2023Q2
1759
150.73M
7.28%
-24.14M
2023Q1
1762
167.48M
7.98%
-13.01M
2022Q4
1782
173.67M
8.19%
-17.14M
Ver Mais
Atividade dos Acionistas
Nome
Ações detidas
Proporção
Variação
Chg %
Data
Dodge & Cox
12.21M
0.61%
-7.21K
-0.05%
Dec 31, 2024
PRIMECAP Management Company
11.02M
0.55%
-983.01K
-8.18%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
8.18M
0.41%
+90.82K
+1.12%
Dec 31, 2024
Loomis, Sayles & Company, L.P.
5.57M
0.28%
-192.67K
-3.33%
Dec 31, 2024
Franklin Mutual Advisers, LLC
4.26M
0.21%
-16.98K
-0.39%
Dec 31, 2024
Wellington Management Company, LLP
3.64M
0.18%
-351.31K
-8.78%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
3.59M
0.18%
-52.88K
-1.45%
Dec 31, 2024
Parametric Portfolio Associates LLC
2.97M
0.15%
-86.17K
-2.81%
Dec 31, 2024
Renaissance Technologies LLC
2.66M
0.13%
+368.17K
+16.00%
Dec 31, 2024
Managed Account Advisors LLC
2.55M
0.12%
-164.18K
-6.03%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: qua, 5 de mar
Tempo de atualização: qua, 5 de mar
Nome
Proporção
VanEck Pharmaceutical ETF
4.92%
Amplify International Enhanced Dividend Income ETF
2.91%
Invesco International Dividend Achievers ETF
2.54%
Altrius Global Dividend ETF
2.31%
SGI Enhanced Global Income ETF
2.31%
Pacer Global Cash Cows Dividend ETF
1.98%
Avantis International Large Cap Value ETF
1.85%
Brandes International ETF
1.48%
SP Funds S&P World (ex-US) ETF
1.42%
Pacer Trendpilot International ETF
1.22%
Ver Mais
VanEck Pharmaceutical ETF
Proporção4.92%
Amplify International Enhanced Dividend Income ETF
Proporção2.91%
Invesco International Dividend Achievers ETF
Proporção2.54%
Altrius Global Dividend ETF
Proporção2.31%
SGI Enhanced Global Income ETF
Proporção2.31%
Pacer Global Cash Cows Dividend ETF
Proporção1.98%
Avantis International Large Cap Value ETF
Proporção1.85%
Brandes International ETF
Proporção1.48%
SP Funds S&P World (ex-US) ETF
Proporção1.42%
Pacer Trendpilot International ETF
Proporção1.22%
Dividendo
Um total de
36.74B
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro das ações
Data de pagamento
Data de ex-dividendo
Feb 12, 2024
NVS.NB Final Cash Dividend of gross USD 3.739544 paid on Apr 19, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Apr 19, 2024
Mar 07, 2024
Feb 02, 2023
NVS.NB Final Cash Dividend of gross USD 3.498699 paid on Mar 20, 2023 going ex on Mar 09, 2023
Mar 10, 2023
Mar 20, 2023
Mar 09, 2023
Feb 04, 2022
NVS.NB Final Cash Dividend of gross USD 3.32525 paid on Mar 17, 2022 going ex on Mar 08, 2022
Mar 09, 2022
Mar 17, 2022
Mar 08, 2022
Jan 26, 2021
NVS.NB Final Cash Dividend of gross USD 3.199072 paid on Mar 15, 2021 going ex on Mar 04, 2021
Mar 05, 2021
Mar 15, 2021
Mar 04, 2021
Jan 31, 2020
NVS.NB Final Cash Dividend of gross USD 3.087366 paid on Mar 12, 2020 going ex on Mar 03, 2020
Mar 04, 2020
Mar 12, 2020
Mar 03, 2020
Desdobramento de Ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados